Development of Electrospinning Membrane Associated to Platelet Lysate as Tissue Engineering Strategy to Veterinary Regenerative Medicine Application

• Grant number: 24/05414-2
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: February 01, 2025
• End date: October 31, 2025
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: João Pedro Hübbe Pfeifer
• Grantee: João Pedro Hübbe Pfeifer
• Company: Soluções em Biotecnologia 3D - Engenharia Tecidual Ltda
• CNAE: Fabricação de medicamentos para uso veterinário ; Pesquisa e desenvolvimento experimental em ciências físicas e naturais
• Associated scholarship(s): 25/00530-7 - Development of electrospinning membrane associated to platelet lysate as Tissue Engineering strategy to Veterinary Regenerative Medicine application, BP.PIPE; 25/00674-9 - Standardization of large-scale preparation of equine platelet lysate and evaluation of a biomaterial based on electrospun bilayer membrane (PLGA/gelatin) associated with equine platelet lysate, BP.TT

Abstract

Tissue engineering has attracted increasing attention as a therapeutic tool in tissue repair in veterinary medicine. In veterinary regenerative medicine, a little explored product is platelet lysate (PL), a product of platelet lysis, rich in growth factors (GF) that help and accelerate the restoration of injured tissues. To improve the therapeutic effect, the association of PL with biomaterial scaffolds can increase the efficiency of drug delivery at the site of injury. Therefore, the objective of this PIPE-Phase 1 is to characterize the electrospun PLGA and gelatin bilayer membrane by associating it with equine platelet lysate (ePL) and evaluate the biocompatibility and efficacy of this product in an in vivo experimental model. To this end, the experiment will be divided into three stages: stage 1 - large scale ePL production, which will involve the collection of equine blood, preparation of the ePL (obtaining the concentrated platelet fraction, centrifugation and freezing and thawing cycles) and the determination of specific growth factors in the final eLP by ELISA/multiplex; stage 2 - preparation of PLGA/gelatin bilayer membranes and association of the ePL with the membrane, followed by evaluation of the integration of the biomaterial by Transmission Electron Microscopy and immunofluorescence; stage 3 - in vivo test following ISO10993-6 and ISO10993-11 standards, surgical induction of wounds will be carried out in an animal model of rats divided into three groups: control, commercial membrane and PLGA/gel/ePL bilayer membrane), with n=6 per group. The animals will be evaluated for systemic and local toxicity, healing rate and histological analysis (H&E, Masson Trichrome and Immunohistochemistry). Based on the results obtained in Phase 1 of PIPE, the aim is to evolve from the level of TRL 3 to TRL 6, overcoming the technological development phase towards demonstrating the technological solution for applications in the veterinary field. The goal is to develop a scalable product with a major impact on animal health and the strategic plan of 3D Biotechnology Solutions (3DBS). (AU)